Article
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
AIDS (London, England) - 18 Oct 2007
Saitoh Akihiko, Sarles Elizabeth, Capparelli Edmund, Aweeka Francesca, Kovacs Andrea, Burchett Sandra K, Wiznia Andrew, Nachman Sharon, Fenton Terence, Spector Stephen A
Abstract excerpt
BACKGROUND: Cytochrome P450 2B6 (CYP2B6)-G516T genotype is associated with altered activity of hepatic CYP2B6 and efavirenz pharmacokinetics, but the relationship between the CYP2B6-G516T genotype and nevirapine (NVP) pharmacokinetics in plasma and cerebrospinal fluid (CSF) is limited. METHODS: In 126 children who received NVP and protease inhibitors from PACTG 366 and 377 cohorts, CYP2B6 and ATP-binding...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
